Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Münch

Showing results (1-10 of 225) with videos related to

Pageof 23
Sort By:
Biospektrum : Zeitschrift Der Gesellschaft Fur Biologishe Chemie (GBCH) Und Der Vereinigung Fur Allgemeine Und Angewandte Mikrobiologie (VAAM)|April 19, 2023
Tatjana Weil, Jan Münch
Trends in Microbiology|August 8, 2015
Improving preclinical models of HIV microbicide efficacyNadia R Roan, Jan Münch
Journal of Virology|April 14, 2005
Human immunodeficiency virus type 1 inhibits DNA damage-triggered apoptosis by a Nef-independent mechanismMichael Schindler, Jan Münch, Frank Kirchhoff
AIDS (London, England)|August 17, 2005
Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitorsRaghavan Chinnadurai, Jan Münch, Frank Kirchhoff
International Journal of Molecular Sciences|February 15, 2022
The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 TreatmentLukas Wettstein, Frank Kirchhoff, Jan Münch
Oncotarget|October 14, 2015
EPI-X4, a novel endogenous antagonist of CXCR4Christian Buske, Frank Kirchhoff, Jan Münch
Journal of Leukocyte Biology|March 12, 2016
Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4Onofrio Zirafi, Patrick C Hermann, Jan Münch
International Journal of Molecular Sciences|November 25, 2023
Conformational States of the CXCR4 Inhibitor Peptide EPI-X4-A Theoretical AnalysisChristoph Karsten Jung, Jan Münch, Timo Jacob
Methods in Molecular Biology (Clifton, N.J.)|October 26, 2013
HIV-1 accessory proteins: NefAnke Heigele, Daniel Sauter, Jan Münch, et al.
Bioorganic & Medicinal Chemistry|November 11, 2017
Exploiting the human peptidome for novel antimicrobial and anticancer agentsMatteo Bosso, Ludger Ständker, Frank Kirchhoff, et al.
Pageof 23

Showing results (1-10 of 225) with videos related to

Sort By:
Pageof 23
Biospektrum : Zeitschrift Der Gesellschaft Fur Biologishe Chemie (GBCH) Und Der Vereinigung Fur Allgemeine Und Angewandte Mikrobiologie (VAAM)|April 19, 2023
Tatjana Weil, Jan Münch
Trends in Microbiology|August 8, 2015
Improving preclinical models of HIV microbicide efficacyNadia R Roan, Jan Münch
Journal of Virology|April 14, 2005
Human immunodeficiency virus type 1 inhibits DNA damage-triggered apoptosis by a Nef-independent mechanismMichael Schindler, Jan Münch, Frank Kirchhoff
AIDS (London, England)|August 17, 2005
Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitorsRaghavan Chinnadurai, Jan Münch, Frank Kirchhoff
International Journal of Molecular Sciences|February 15, 2022
The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 TreatmentLukas Wettstein, Frank Kirchhoff, Jan Münch
Oncotarget|October 14, 2015
EPI-X4, a novel endogenous antagonist of CXCR4Christian Buske, Frank Kirchhoff, Jan Münch
Journal of Leukocyte Biology|March 12, 2016
Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4Onofrio Zirafi, Patrick C Hermann, Jan Münch
International Journal of Molecular Sciences|November 25, 2023
Conformational States of the CXCR4 Inhibitor Peptide EPI-X4-A Theoretical AnalysisChristoph Karsten Jung, Jan Münch, Timo Jacob
Methods in Molecular Biology (Clifton, N.J.)|October 26, 2013
HIV-1 accessory proteins: NefAnke Heigele, Daniel Sauter, Jan Münch, et al.
Bioorganic & Medicinal Chemistry|November 11, 2017
Exploiting the human peptidome for novel antimicrobial and anticancer agentsMatteo Bosso, Ludger Ständker, Frank Kirchhoff, et al.
Pageof 23